Zhimeng Biopharma
Latest round
- Series B
Last raised
- Nov 2021
Total raised
- $90M
Investors
- 16
About Zhimeng Biopharma
Established in 2017 and based in Shanghai, China, Zhimeng Biopharma is a medicines' developer that focuses on chronic hepatitis B., Ltd., Ltd. The company's main products include anti-hepatitis B virus (HBV) drugs. Anti-hepatitis B virus (HBV) drugs include HBV nucleocapsid inhibitors, HBV RNA destabilizers and TLR8 agonists. The company’s revenue is generated by providing anti-hepatitis B virus (HBV) drugs.
Who invested in Zhimeng Biopharma
16 investors across 3 rounds
See all investors in Zhimeng Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Zhimeng Biopharma
Who invested in Zhimeng Biopharma?
Zhimeng Biopharma has 16 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Zhimeng Biopharma raised?
Zhimeng Biopharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Zhimeng Biopharma last raise money?
Zhimeng Biopharma's most recent round on record is a Series B, in Nov 2021.
What does Zhimeng Biopharma do?
Established in 2017 and based in Shanghai, China, Zhimeng Biopharma is a medicines' developer that focuses on chronic hepatitis B.
Where is Zhimeng Biopharma headquartered?
Zhimeng Biopharma is headquartered in Shanghai, China.
Which VCs invest in companies like Zhimeng Biopharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Zhimeng Biopharma's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Zhimeng Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.